

Supplementary Data

Novel 2-substituted-benzimidazole-6-sulfonamides as carbonic anhydrase inhibitors: synthesis, biological evaluation against isoforms I, II, IX and XII and molecular docking studies

Ciro Milite,^{1,a} Giorgio Amendola,^{2,a} Alessio Nocentini,³ Silvia Bua,³ Alessandra Cipriano,^{1,4} Elisabetta Barresi,⁵ Alessandra Feoli,¹ Ettore Novellino,⁶ Federico Da Settimo,⁵ Claudiu T. Supuran,³ Sabrina Castellano,^{1,*} Sandro Cosconati,^{2,**} and Sabrina Taliani⁵

¹ *Department of Pharmacy, Epigenetic Med Chem Lab, University of Salerno, via Giovanni Paolo II 132, I-84084 Fisciano (SA), Italy*

² *DiSTABiF, Università della Campania Luigi Vanvitelli, Via Vivaldi 43, 81100 Caserta, Italy.*

³ *NEUROFARBA Department, Sezione di Scienze Farmaceutiche e Nutraceutiche, Università degli Studi di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino (Florence), Italy;*

⁴ *PhD Program in Drug Discovery and Development, University of Salerno, Via Giovanni Paolo II 132, I-84084 Fisciano (SA), Italy*


⁵ *Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.*

⁶ *Department of Pharmacy, University Federico II of Naples, Via D. Montesano 49, 80131 Naples, Italy*

Table of Contents:

- Preparation of compound **28b**: **S3**
- ^1H -NMR and ^{13}C -NMR spectra of compound **6–19**: **S5–S32**

Preparation of 3-(4-Hydroxy-3-(methoxycarbonyl)phenyl)propanoic acid (28b)



(a) Toluene, 18 h (98%); (b) ammonium formate, Pd/C 10 %, MeOH, reflux, 4 h (98%); (c) DCM/TFA (9:1), r.t. 3 h (99%).

Methyl (E)-5-(3-(tert-butoxy)-3-oxoprop-1-en-1-yl)-2-hydroxybenzoate (36)

To a suspension of methyl 5-formyl-2-hydroxybenzoate (400 mg, 2.22 mmol) in 25 mL of toluene, tert-butyl(triphenylphosphoranylidene)acetate (1.67 g, 4.44 mmol) was added and the resulting mixture was stirred at room temperature for 18h. Solvent was evaporated and the crude material was purified by silica gel chromatography (DCM/EtOAc, 9/1) yielding **36** as a white solid (605 mg, 98%). ¹H NMR (400 MHz, CDCl₃) δ 10.95 (s, 1H), 8.00 (d, J = 2.3 Hz, 1H), 7.63 (dd, J = 8.7, 2.3 Hz, 1H), 7.51 (d, J = 15.9 Hz, 1H), 6.99 (d, J = 8.7 Hz, 1H), 6.27 (d, J = 16.0 Hz, 1H), 3.98 (s, 3H), 1.53 (s, 9H). ESI m/z: 279 [M+H]⁺.

Methyl 5-(3-(tert-butoxy)-3-oxopropyl)-2-hydroxybenzoate (37)

To a stirred suspension of **36** (550 mg, 1.97 mmol) in 120 mL of MeOH, ammonium formate (1.24 g, 19.7 mmol) and palladium on carbon 10 % wt. (36 mg) were added. The resulting mixture was heated at reflux for 4 h. After cooling, the mixture was filtered, and the solvent evaporated under reduced pressure. The crude material was taken up with 100 mL of water and extracted with EtOAc (3 x 60 mL). The combined organic phases were washed with brine, dried over Na₂SO₄, filtered and evaporated. The product, obtained as a white solid (540 mg, 98%), was used for the next step without further purification. ¹H NMR (400 MHz, CDCl₃) δ 10.62 (s, 1H), 7.69 (d, 1H, J = 1.5 Hz), 7.33 (d, J = 8.5 Hz, 2H), 6.93 (dd, J = 8.5, 1.5 Hz, 1H), 3.96 (s, 3H), 2.87 (t, J = 7.5 Hz, 2H), 2.53 (t, J = 7.6 Hz, 2H), 1.44 (s, 9H). ESI m/z: 281 [M+H]⁺.

3-(4-Hydroxy-3-(methoxycarbonyl)phenyl)propanoic acid (28b)

Compound **37** (500 mg, 1.78 mmol) was dissolved in a mixture of DCM/TFA (5 mL, 9/1) and the resulting solution was stirred at room temperature for 3 h. Solvent was evaporated yielding essentially pure **28b** (400 mg, 99%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 10.65 (s, 1H), 7.71 (s, 1H), 7.34 (d, J = 8.5 Hz, 1H), 6.95 (d, J = 8.5 Hz, 1H), 3.97 (s, 3H), 2.92 (t, J = 7.6 Hz, 2H), 2.68 (t, J = 7.6 Hz, 2H). ESI m/z: 225 [M+H]⁺.

